269 related articles for article (PubMed ID: 36221119)
21. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
22. Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.
Mellai M; Annovazzi L; Bisogno I; Corona C; Crociara P; Iulini B; Cassoni P; Casalone C; Boldorini R; Schiffer D
Cells; 2020 Jun; 9(6):. PubMed ID: 32599896
[TBL] [Abstract][Full Text] [Related]
23. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
25. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of Thrombomodulin mRNA in High-Grade Soft Tissue Sarcomas after 10 years.
Asanuma K; Nakamura T; Asanuma Y; Okamoto T; Kakimoto T; Yada Y; Hagi T; Kita K; Nakamura K; Matsumine A; Sudo A
Orthop Surg; 2020 Dec; 12(6):1726-1732. PubMed ID: 33015987
[TBL] [Abstract][Full Text] [Related]
27. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
28. Elevated Controlling Nutritional Status (CONUT) Score is Associated with Poor Long-term Survival in Patients with Low-grade Soft-tissue Sarcomas Treated with Surgical Resection.
Liang Y; Hou T; Que Y; Zhao B; Xiao W; Zhang X; Zhou Z
Clin Orthop Relat Res; 2019 Oct; 477(10):2287-2295. PubMed ID: 31107315
[TBL] [Abstract][Full Text] [Related]
29. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
30. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
Harrer DC; Dörrie J; Schaft N
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
[TBL] [Abstract][Full Text] [Related]
31. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer.
Hsu NC; Nien PY; Yokoyama KK; Chu PY; Hou MF
Biochem Biophys Res Commun; 2013 Nov; 441(2):514-8. PubMed ID: 24177010
[TBL] [Abstract][Full Text] [Related]
32. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.
Judge SJ; Bloomstein JD; Sholevar CJ; Darrow MA; Stoffel KM; Vick LV; Dunai C; Cruz SM; Razmara AM; Monjazeb AM; Rebhun RB; Murphy WJ; Canter RJ
Front Immunol; 2022; 13():893177. PubMed ID: 35874727
[TBL] [Abstract][Full Text] [Related]
33. Correlative Study on the Relationship between the Expression of m6a-Related Genes and the Prognosis and Immunotherapy of Soft Tissue Sarcoma.
Qiu Y; Li J; Yao J; Meng J; Huang X; Zheng X; Wen Z; Huang J; Wang H
Biomed Res Int; 2022; 2022():5439023. PubMed ID: 38024481
[TBL] [Abstract][Full Text] [Related]
34. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
35. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
37. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.
Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA
PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730
[TBL] [Abstract][Full Text] [Related]
38. Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.
Kropp KN; Fatho M; Huduti E; Faust M; Lübcke S; Lennerz V; Paschen A; Theobald M; Wölfel T; Wölfel C
Front Immunol; 2023; 14():1245559. PubMed ID: 37849763
[TBL] [Abstract][Full Text] [Related]
39. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
Wood GE; Meyer C; Petitprez F; D'Angelo SP
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
